2023
DOI: 10.3390/md21080433
|View full text |Cite
|
Sign up to set email alerts
|

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Nallupillai Paramakrishnan,
Khian Giap Lim,
Yamunna Paramaswaran
et al.

Abstract: Alzheimer’s disease (AD) is a major type of dementia disorder. Common cognitive changes occur as a result of cerebrovascular damage (CVD) via the disruption of matrix metalloproteinase-13 (MMP-13). In diabetic cases, the progress of vascular dementia is faster and the AD rate is higher. Patients with type 2 diabetes are known to have a higher risk of the factor for AD progression. Hence, this study is designed to investigate the role of astaxanthin (AST) in CVD-associated AD in zebrafish via the inhibition of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 58 publications
0
1
0
Order By: Relevance
“…JNJ0966 can inhibit the activation of MMP9 zymogen and the subsequent generation of catalytically active enzymes ( Scannevin et al, 2017 ), while MMP-9-IN-1 binds to the hemopexin (PEX) domain of MMP-9 resulting in the abrogation of MMP-9 homodimerization and blockage of a downstream signaling pathway required for MMP-9-mediated cell migration ( Dufour et al, 2011 ). CL-82198 is a highly selective MMP13 inhibitor ( Paramakrishnan et al, 2023 ), which has been used to treat Alzheimer’s disease ( Paramakrishnan et al, 2023 ), liver fibrosis ( George et al, 2017 ), chronic periodontitis ( Hernandez Rios et al, 2009 ). However, the effect of these inhibitors on human arthritis is still in need of further investigation.…”
Section: Mmps and Drug In Rheumatoid Arthritismentioning
confidence: 99%
“…JNJ0966 can inhibit the activation of MMP9 zymogen and the subsequent generation of catalytically active enzymes ( Scannevin et al, 2017 ), while MMP-9-IN-1 binds to the hemopexin (PEX) domain of MMP-9 resulting in the abrogation of MMP-9 homodimerization and blockage of a downstream signaling pathway required for MMP-9-mediated cell migration ( Dufour et al, 2011 ). CL-82198 is a highly selective MMP13 inhibitor ( Paramakrishnan et al, 2023 ), which has been used to treat Alzheimer’s disease ( Paramakrishnan et al, 2023 ), liver fibrosis ( George et al, 2017 ), chronic periodontitis ( Hernandez Rios et al, 2009 ). However, the effect of these inhibitors on human arthritis is still in need of further investigation.…”
Section: Mmps and Drug In Rheumatoid Arthritismentioning
confidence: 99%